Journal of Clinical Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 7, 2025
The
Oncology
Grand
Rounds
series
is
designed
to
place
original
reports
published
in
the
Journal
into
clinical
context.
A
case
presentation
followed
by
a
description
of
diagnostic
and
management
challenges,
review
relevant
literature,
summary
authors'
suggested
approaches.
goal
this
help
readers
better
understand
how
apply
results
key
studies,
including
those
Clinical
Oncology,
patients
seen
their
own
practice.
Cancers,
Год журнала:
2025,
Номер
17(3), С. 353 - 353
Опубликована: Янв. 22, 2025
Targeted
therapies
have
changed
the
treatment
landscape
of
non-small-cell
lung
cancer
and
led
to
improved
patient
survival
across
all
stages
cancer.
Newer
advances
in
common
novel
oncogenic
drivers
continue
occur
at
vigorous
speed,
making
it
challenging
stay
up
date
with
rapidly
evolving
field.
In
this
article,
we
review
emerging
perspectives
actionable
targets
We
focus
on
development
newer
KRAS-directed
therapies,
particularly
non-G12C
mutations,
pan-RAS
inhibitors,
RAS-GTP
inhibitors.
also
describe
current
standard
care
for
EGFR-
ALK-altered
NSCLC
dive
into
treatments
expected
be
clinic
soon.
A
similar
approach
is
taken
toward
MET,
HER2,
RET,
ROS1,
FGFR
alterations
as
Finally,
conclude
body
evidence
targeting
TROP-2
a
target,
potentially
importance
post-targeted
therapy
scenarios.
Biomedicines,
Год журнала:
2025,
Номер
13(2), С. 470 - 470
Опубликована: Фев. 14, 2025
Tyrosine
kinase
inhibitors
(TKIs)
have
transformed
the
treatment
of
epidermal
growth
factor
receptor
(EGFR)-mutant
non-small
cell
lung
cancer.
However,
resistance
remains
a
major
challenge
in
clinical
practice.
The
tumor
microenvironment
(TME)
is
complex
system
composed
cells,
immune
and
non-immune
non-cellular
components.
Evidence
indicates
that
dynamic
changes
TME
during
TKI
are
associated
with
development
resistance.
Research
has
focused
on
identifying
how
each
component
interacts
tumors
TKIs
to
understand
therapeutic
targets
could
address
In
this
review,
we
describe
components,
such
as
fibroblasts,
blood
vessels,
checkpoint
proteins,
cytokines,
interact
EGFR-mutant
they
can
promote
TKIs.
Furthermore,
discuss
potential
strategies
targeting
novel
approach.
Current Oncology,
Год журнала:
2025,
Номер
32(3), С. 146 - 146
Опубликована: Март 2, 2025
Lung
cancer
treatment
has
changed
in
the
last
twenty
years
since
discovery
of
EGFR
mutations.
In
this
article,
we
will
review
current
state
art
for
non-small
cell
lung
(NSCLC)
actionable
genomic
alterations
(AGA).
AGAs
are
mostly
found
adenocarcinomas,
a
subtype
cancers.
We
focus
on
mutations,
ALK
fusions,
ROS1
BRAF
V600E
MET
exon
14-skipping
RET
KRAS
G12C
ERBB2
mutations
(also
called
HER2
mutations),
and
NTRK
fusions.
also
touch
key
toxicities
associated
with
these
medications.
Treatments
available
metastatic
stage,
but
discuss
adjuvant
therapy
as
well
stage
III
post-chemoradiotherapy
cancer.
Journal of Clinical Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 7, 2025
The
Oncology
Grand
Rounds
series
is
designed
to
place
original
reports
published
in
the
Journal
into
clinical
context.
A
case
presentation
followed
by
a
description
of
diagnostic
and
management
challenges,
review
relevant
literature,
summary
authors'
suggested
approaches.
goal
this
help
readers
better
understand
how
apply
results
key
studies,
including
those
Clinical
Oncology,
patients
seen
their
own
practice.
